Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

Concerted IL-25R and IL-4Rα signaling drive innate type 2 effector immunity for optimal helminth expulsion.

Katherine A Smith | Stephan Löser | Fumi Varyani | Yvonne Harcus | Henry J McSorley | Andrew Nj McKenzie | Rick M Maizels
eLife | 2018

Interleukin 25 (IL-25) is a major 'alarmin' cytokine, capable of initiating and amplifying the type immune response to helminth parasites. However, its role in the later effector phase of clearing chronic infection remains unclear. The helminth Heligmosomoides polygyrus establishes long-term infections in susceptible C57BL/6 mice, but is slowly expelled in BALB/c mice from day 14 onwards. We noted that IL-25R (Il17rb)-deficient BALB/c mice were unable to expel parasites despite type 2 immune activation comparable to the wild-type. We then established that in C57BL/6 mice, IL-25 adminstered late in infection (days 14-17) drove immunity. Moreover, when IL-25 and IL-4 were delivered to Rag1-deficient mice, the combination resulted in near complete expulsion of the parasite, even following administration of an anti-CD90 antibody to deplete innate lymphoid cells (ILCs). Hence, effective anti-helminth immunity during chronic infection requires an innate effector cell population that is synergistically activated by the combination of IL-4Rα and IL-25R signaling.

Pubmed ID: 30238872

Associated grants

  • Agency: Wellcome Trust, United Kingdom
    Id: 104111
  • Agency: European Commission, International
    Id: 657639
  • Agency: Medical Research Council, United Kingdom
    Id: MC_U105178805
  • Agency: Wellcome Trust, United Kingdom
    Id: 106122
  • Agency: Wellcome, International
    Id: 90281
  • Agency: Wellcome Trust, United Kingdom
    Id: 090281
  • Agency: Wellcome Trust, United Kingdom
  • Agency: Wellcome, International
    Id: 106122
  • Agency: Wellcome, International
    Id: 090281

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Bio X Cell (tool)

RRID:SCR_004997

Commercial supplier and developer of in vivo antibodies. Provides antibodies and antibody production services.

View all literature mentions

PeproTech (tool)

RRID:SCR_006802

An Antibody supplier

View all literature mentions

BD Biosciences (tool)

RRID:SCR_013311

An Antibody supplier

View all literature mentions

Tg(Cd8a*-cre)B8Asin; Il7rtm1.1Asin/Il7rtm1Imx; Il4ratm1Sz/Il4ratm1Sz (tool)

RRID:MGI:5469008

Allele Detail: Targeted, Transgenic This is a legacy resource.

View all literature mentions

B6.129S7-Rag1tm1Mom/J (tool)

RRID:IMSR_JAX:002216

Mus musculus with name B6.129S7-Rag1tm1Mom/J from IMSR.

View all literature mentions

C57BL/6J (tool)

RRID:IMSR_JAX:000664

Mus musculus with name C57BL/6J from IMSR.

View all literature mentions

BALB/cAnNCrl (tool)

RRID:MGI:2683685

laboratory mouse with name BALB/cAnNCrl from MGI.

View all literature mentions